November 17, 2026 · Lancet (London, England) · DOI: 10.1016/S0140-6736(26)01806-4

Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.

Listen to this summary

This first-in-human phase 1 trial tested TriPRIL, an autologous CAR T-cell therapy that uses an engineered trimeric form of the natural ligand APRIL to simultaneously target BCMA and TACI, aiming to reduce antigen escape in relapsed or refractory multiple myeloma. In 15 infused patients (nine of whom had prior BCMA-directed CAR T therapy), the therapy showed a manageable safety profile, with no dose-limiting toxicities or treatment-related deaths, and cytokine release syndrome was limited to grade 1-2. The recommended phase 2 dose was set at 3.0 × 10^8 cells, supporting further investigation of this dual-targeted, natural ligand-based approach.

Benjamin R Puliafito, Charlotte E Graham, Noopur S Raje, Andrew J Yee, Diana D Cirstea, Andrew R Branagan, Nora K Horick, Aiyana L Parker, Maxx King, Marisa G Ogier, Mark B Leick, Sarah Nikiforow, Kathleen M E Gallagher, Matthew J Frigault, Marcela V Maus

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play